Composition comprising at least one nucleosidic moiety as a therapeutic agent, and CKC

1. A composition comprising at least one oligonucleotide and cetalkonium chloride (CKC), wherein the ratio of CKC to mers of the oligonucleotide is below 0.55.

2. The composition according to claim 1 , wherein the oligonucleotide comprises 5 to 50 nucleotides.

3. The composition according to claim 1 , wherein the oligonucleotide is a short interfering RNA.

4. The composition according to claim 1 , further comprising at least one other therapeutic agent.

5. The composition according to claim 1 , wherein the oligonucleotide is within a colloidal system comprising emulsions, micelles, inverted micelles, or block or non-block polymer micelles.

6. The composition according to claim 1 , wherein the oligonucleotide is associated in the composition with at least one of a particle, nanoparticle, sphere, nanosphere, capsule or nanocapsule, liposomes, niosomes, or oleosomes.

7. The composition according to claim 1 , wherein the composition is in the form of a submicronic oil-in-water emulsion comprising an oil, and at least one surfactant.

8. The composition according to claim 7 , wherein the surfactant is selected from tyloxapol, polysorbate 80, montane 20, poloxamer, cremophor and/or lecithins.

9. The composition according to claim 7 , wherein the amount of surfactant in the composition is in a range from 0.001% to 5% by weight to the total weight of the composition.

10. The composition according to claim 7 , wherein the oil-in-water emulsion comprises only one surfactant.

11. The composition according to claim 1 , wherein the ratio CKC/number of mers of the oligonucleotide is from 0.001 to 0.5.

12. A medicament comprising an effective amount of at least one oligonucleotide and cetalkonium chloride (CKC), wherein the ratio of CKC to mers of the oligonucleotide is less than 0.55.

13. A pharmaceutical composition comprising an effective amount of at least one oligonucleotide, and cetalkonium chloride (CKC), in combination with one or more pharmaceutically acceptable excipients, wherein the ratio of CKC to mers of the oligonucleotide is less than 0.55.

14. The medicament according to claim 12 , wherein the oligonucleotide is an antisense oligonucleotide directed against specific cellular receptors.

15. A method for the prevention, treatment or relief of eye, lung, and/or respiratory tract conditions, comprising administering the composition of claim 1 to a patient in need thereof.

16. The method according to claim 15 , wherein the composition is administered directly or otherwise, to all or a portion of the alimentary canal, skin, eyes, pulmonary tract, respiratory tract, or to the mucosa, of an animal.

17. A method to enhance stability and/or improve penetration of nucleosidic moieties within targeted cells, comprising administering the composition of claim 1 to a patient in need thereof.

18. The pharmaceutical composition according to claim 13 , wherein the oligonucleotide is an antisense oligonucleotide directed against specific cellular receptors.